EMD Serono Makes Key Oncology Appointments

David Trexler has been appointed senior vice president of Oncology Commercial at EMD Serono. Mr. Trexler will lead the strategy for the oncology franchise and will be responsible for maximizing growth opportunities by building an oncology team focused on customer and patient centricity.
 
Mr. Trexler has more than 25 years of experience in branded pharmaceutical marketing, sales and business development. He joins the company from Eisai, Inc., where he served as senior vice president of the Americas Oncology Business Unit. Mr. Trexler previously held senior leadership roles at Mylan Bertek Pharmaceuticals and Sanofi-Aventis.
 
Additionally, Dr. Zhen Su has been appointed vice president of Oncology Medical to lead the medical strategy and team for the franchise. Dr. Su has more than 15 years of experience, with strong clinical expertise in oncology, immuno-oncology and urology. He has held positions in academic and pharmaceutical medicine, including general management, clinical development, medical affairs and business development. Dr. Su previously served as associate vice president and global head of Jevtana (cabazitaxel) at Sanofi. Dr. Su also held several academic positions, including assistant professor of Surgery at Duke University, where he also received his fellowship in oncology.  
 
“This is an exciting time for the oncology franchise of EMD Serono as we initiated our commercial presence in the United States and continue to advance our pipeline,” said Paris Panayiotopoulos, president and managing director of EMD Serono. “Our long-standing commitment and focus on specialty care is a driving force behind our expansion in oncology. The experience and passion that David and Zhen possess aligns perfectly with our commitment to address challenging cancers, champion patient care and forge a new path in oncology management.”